Big Bucks Being Made on Cancer Pain
The New York Times brings us another example of how those drug companies that the president loves so much are ripping off the elderly.N.Y. Times
:
On Feb. 3, Joyce Elkins filled a prescription for a two-week supply of nitrogen mustard, a decades-old cancer drug used to treat a rare form of lymphoma. The cost was $77.50.
On Feb. 17, Ms. Elkins, a 64-year-old retiree who lives in Georgetown, Tex., returned to her pharmacy for a refill. This time, following a huge increase in the wholesale price of the drug, the cost was $548.01.
Ms. Elkins’s insurance does not cover nitrogen mustard, which she must take for at least the next six months at a cost that will now total nearly $7,000. She and her husband, who works for the Texas Department of Transportation, are paying for the medicine by spending less on utilities and food, she said.
Dig, Root, GrowThis year, we’re all on shaky ground, and the need for independent journalism has never been greater. A new administration is openly attacking free press — and the stakes couldn’t be higher.
Your support is more than a donation. It helps us dig deeper into hidden truths, root out corruption and misinformation, and grow an informed, resilient community.
Independent journalism like Truthdig doesn't just report the news — it helps cultivate a better future.
Your tax-deductible gift powers fearless reporting and uncompromising analysis. Together, we can protect democracy and expose the stories that must be told.
Dig. Root. Grow. Cultivate a better future.
Donate today.
Editorial Cartoons
Editorial Cartoons
Visit Ann Telnaes’ Substack Open Windows for more.
Health & Wellness
Frequent exposure to plastic chemicals — especially through food packaging — makes potential impacts more concerning, say researchers.
Editorial Cartoons
Film
Cinema’s most striking colorist paints a scene from the end of life.
Environment
Though it causes more cancer than any other toxic air pollutant, little is being done to curb the risk posed by the ubiquitous gas.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.